Products are for research use only, not for human use

Science

Eloralintide: The Amylin Agonist in Phase 3, and Why It Is the Hardest Compound to Verify

Eloralintide inverts the usual trade-off: a randomised 48-week trial in the Lancet, nine phase 3 studies recruiting, and almost no independent analytical infrastructure. Why amylin is not an incretin, and what a certificate for a compound still in development can prove.

Marcus Hopkin, PhD, Director of Research and Development at Volta Peptides.

Written by Marcus Hopkin, PhD

Director of Research and Development, Volta Peptides

November 19, 202616 min read

Key Takeaways

  • •Eloralintide, development code LY3841136, is a selective amylin receptor agonist from Eli Lilly, with CAS 2883634-40-8, formula C201H319N49O65S2 and an average mass of 4526 g/mol. Amylin is a pancreatic hormone co-secreted with insulin, not an incretin, and acts at calcitonin receptor complexes.
  • •"Selective" is a measured fold-preference, not an absence of activity. In human receptor cell lines the discovery paper reports a 12-fold preference for the AMY1 receptor over the calcitonin receptor and 11-fold over AMY3.
  • •Structurally it is a lipidated amylin analogue with a thioacetal bridge, not a disulfide. Its two cysteines are joined through a methylene group, and a C20 fatty diacid is attached through a linker, which matters for every identity check.
  • •Phase 2 results are published in the Lancet: in a 48-week double-blind trial in 263 adults without type 2 diabetes, mean body weight fell by 9% to 20% across eloralintide arms against 0.4% on placebo (efficacy estimand). A 367-participant phase 2b in type 2 diabetes, combining it with GLP-2 TZ, reported a 23.3% mean reduction in its highest combination arm in September 2026, not yet peer reviewed.
  • •The programme is in active phase 3 and holds no marketing authorization anywhere. Twenty-six registered studies carry its name or its development code, including eight phase 3 trials in the ENLIGHTEN and AMPLIFY programmes, six of them recruiting as of 14 November 2026 and four with Canadian sites.
  • •It is the hardest compound here to verify, because no pharmacopoeial monograph and no widely circulating independent reference standard exist for a molecule still in development.

Summary

Eloralintide (LY3841136) is Eli Lilly's selective amylin receptor agonist, and amylin is a pancreatic hormone, not an incretin. A 48-week phase 2 trial is published in the Lancet, a combination phase 2b in type 2 diabetes reported topline results in September 2026, and eight phase 3 trials carry its name, six recruiting as of 14 November 2026. It holds no marketing authorization anywhere. Because it is still in development, no pharmacopoeial monograph or independent reference standard exists, which makes it the hardest compound on the shelf to verify: ask what reference the identity was established against.

Eloralintide is the newest compound on a research shelf and the only one inside an active phase 3 programme at a major pharmaceutical company. That makes it the reverse of every other compound in this series. The others have decades of literature and no development; this one has an unfinished clinical programme, phase 2 results published in the Lancet, and almost no independent analytical history. It is also routinely filed with the incretin compounds, which it is not.

This guide covers what eloralintide is, why an amylin receptor agonist is a different class from an incretin receptor agonist, exactly what the phase 2 trial reported, where the phase 3 programme stands as of November 2026, how it compares with the other amylin compounds in development, and why a compound in active development is the hardest kind of material to verify. It is written for laboratory and in-vitro research procurement. It reports what published studies recorded because that is the public evidence base, and it contains no dosing, administration or human-use guidance, and none should be inferred.

What Eloralintide Is

PropertyValue
Development codeLY3841136
OriginatorEli Lilly and Company
ClassSelective amylin receptor agonist
CAS number2883634-40-8
Molecular formulaC201H319N49O65S2
Average mass4526 g/mol
Monoisotopic mass4523.2604 Da
FormLyophilized powder

Those values agree with PubChem CID 175663130. The CAS number agrees with the figure on Volta's own product page; the formula and mass are available from PubChem and are worth recording alongside it.

At 4526 daltons the molecule is in the long-peptide range, comparable to tesamorelin at 5136 and well above the short peptides that dominate a research shelf. Two structural features account for much of that mass, and both matter for verification.

The ring is a thioacetal, not a disulfide. Native human amylin closes a ring with a disulfide between its second and seventh residues. Eloralintide keeps a ring of the same size near its N-terminus but joins the two cysteine sulfurs through a methylene group, Cys-S-CH2-S-Cys, which is what PubChem's structure and systematic name record. A thioacetal cannot be reduced back to two free thiols the way a disulfide can, and it makes the molecule 14 daltons heavier than the same sequence closed with an ordinary disulfide.

It is lipidated. A twenty-carbon fatty diacid is attached to the peptide through a linker of two gamma-glutamyl units and an aminohexanoyl spacer. Fatty-acid acylation is a common way to lengthen a peptide's circulating life, and the phase 1 paper describes eloralintide as long-acting, with a half-life of about two weeks.

Structural featureEloralintideCagrilintideNative human amylin
Ring closureMethylene thioacetal (Cys-S-CH2-S-Cys)DisulfideDisulfide, Cys2 to Cys7
Fatty-acid acylationC20 diacid via a gamma-Glu-gamma-Glu-aminohexanoyl linkerC20 diacidNone
FormulaC201H319N49O65S2C194H312N54O59S2C165H261N51O55S2
Average mass4526 g/mol4409 g/mol3903.3 g/mol

The cagrilintide and amylin figures are from PubChem CIDs 171397054 and 16132430.

Amylin Is Not an Incretin

This is the classification error that matters, and it is almost universal in consumer-facing content about the compound.

Amylin, also called islet amyloid polypeptide, is a 37-residue hormone co-secreted with insulin from pancreatic beta cells. The incretins are a different set of hormones, secreted from the gut in response to food, acting at their own receptors. Both are involved in the physiology of feeding and glucose handling, which is why they end up in the same commercial conversation, but they are distinct hormones with distinct receptors.

The receptor pharmacology is where the distinction becomes concrete. Amylin acts at receptor complexes formed when the calcitonin receptor associates with receptor activity-modifying proteins. Different RAMP partners produce different complexes with different ligand preferences, and the calcitonin receptor alone has its own activity. So an amylin receptor is not one protein but a family of assemblies sharing a core, and selectivity among them is a genuine pharmacological achievement rather than marketing language. That is what "selective amylin receptor agonist" is claiming, and the discovery paper puts numbers on it: in cell lines expressing a single human receptor, eloralintide activated AMY1 12-fold more potently than the calcitonin receptor and 11-fold more potently than AMY3 (PMID 41109426). Selectivity is a ratio, not an off switch, and it was species-dependent: at the rat receptors, AMY1 and AMY3 were both activated more potently than the calcitonin receptor. The same paper reports less conditioned taste avoidance in lean rats than with cagrilintide, a non-selective comparator, which is the preclinical basis for the tolerability argument the class is being developed on.

A reader who files eloralintide with the incretin compounds will draw wrong conclusions in both directions: expecting the pharmacology of a class it does not belong to, and missing that the clinical programme includes combination work precisely because the two mechanisms are separate.

Two pancreatic islet cells releasing two different hormone molecules side by side, with a separate gut cell releasing a third, illustrating that amylin is co-secreted with insulin from the pancreas while the incretins come from the gut
Two pancreatic islet cells releasing two different hormone molecules side by side, with a separate gut cell releasing a third, illustrating that amylin is co-secreted with insulin from the pancreas while the incretins come from the gut

Where Development Actually Stands

QuestionAnswer
FDA-approved drug productNo
Marketing authorization anywhereNo
Health Canada Drug Product Database entryNone
Highest phase reachedPhase 3, recruiting
Phase 2 results publishedYes, Lancet, 2025
Supplied asResearch material, in vitro use only

A search of ClinicalTrials.gov on 14 November 2026 for the name and for the development code LY3841136 returns twenty-six registered studies across every phase; the earliest are registered under the code alone, which is why a search by name finds fewer. The phase 3 programme runs under two banners, ENLIGHTEN for the single agent and AMPLIFY for a co-formulated combination with GLP-2 TZ, which Lilly calls EloraTZP:

TrialProgrammePopulationEnrolmentStatusPrimary completionCanadian sites
NCT07282600ENLIGHTEN-2Obesity or overweight with type 2 diabetes1,035Recruiting since Dec 2025Jan 2028None listed
NCT07321886ENLIGHTEN-1Obesity, or overweight without type 2 diabetes1,980Recruiting since Feb 2026Mar 20289
NCT07369011ENLIGHTEN-3Obstructive sleep apnoea with obesity or overweight800Recruiting since Feb 2026Mar 20286
NCT07353931ENLIGHTEN-4Osteoarthritis knee pain with obesity or overweight900Recruiting since Feb 2026Mar 20287
NCT07392190ENLIGHTEN-6Persistent obesity on a weekly incretin agonist900Recruiting since Feb 2026Jun 2028None listed
NCT07900633ENLIGHTEN-10Obesity or overweight with type 2 diabetes and increased cardiovascular risk3,000Not yet recruiting, December 2026Nov 202911
NCT07881458AMPLIFY-2Obesity or overweight with type 2 diabetes1,000Recruiting since Oct 2026Oct 2029None listed
NCT07881432AMPLIFY-1Obesity without type 2 diabetes2,115Not yet recruiting, December 2026Oct 2029None listed

Four of the eight list Canadian sites, in Brampton, Calgary, Guelph, Lévis, Quebec City and elsewhere, so the programme is enrolling in Canada even though nothing about the compound is authorized here: Health Canada's Drug Product Database has no entry for eloralintide.

Behind those sit the completed studies the programme was built on: NCT06230523, the 263-participant phase 2 against placebo that ran from February 2024; NCT06603571, a 367-participant phase 2b in adults with type 2 diabetes comparing eloralintide, GLP-2 TZ and the two together against placebo over 48 weeks, completed in July 2026; and NCT06916065, a 188-participant phase 1 that included a combination arm. Two further phase 2 studies pair eloralintide with Lilly's investigational compound macupatide (LY3532226): NCT07215559 in adults with type 2 diabetes and NCT07589608, recruiting since May 2026. A further set of phase 1 studies in renal impairment, hepatic impairment and specific populations is active, and another (NCT07935304) was first posted on 13 November 2026.

That is an active, broad, late-stage programme, and the breadth is itself informative: sleep apnoea and knee osteoarthritis are indications a sponsor pursues when it expects an effect on body weight to carry into conditions driven by it. It is also the reason the compound holds no approval: a drug in recruiting phase 3 trials has not completed the evidence package a regulator reviews. Research-grade material is not the investigational product supplied in those trials, which is manufactured to clinical standards under a regulatory submission and dispensed only within a protocol.

The practical consequence for a research buyer is that this compound's position will change, possibly more than once, within the ordinary life of a page about it. Any regulatory statement about eloralintide should be read with its date attached.

What the Published Research Measured

The literature is small, recent and of high quality, which is an unusual combination on a research shelf.

  • Discovery through clinical proof of concept is covered in Molecular Metabolism in 2025, under the title "Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept" (PMID 41109426). This is the paper that establishes the selectivity claim and the preclinical characterization.
  • Phase 1 proof of concept appeared in Diabetes, Obesity and Metabolism in 2026, describing it as a selective, long-acting amylin receptor agonist (PMID 41559929). The 12-week multiple ascending study enrolled 100 participants at three US centres, found exposure proportional across the range tested, and recorded body weight changes of 2.6% to 11.3% across cohorts at week 12; the discovery paper adds a single ascending study in 48 healthy participants (NCT05295940). The phase 1 paper also reports a terminal half-life of about two weeks; a fall in mean heart rate in the highest cohort at week 12, by 14.4 beats per minute against 3.4 on placebo; a modest lowering of acetaminophen exposure after the first administration that the authors read as a possibly transient effect on gastric emptying; and mood-related adverse events in four participants, each resolving within two to four days. Of 22 participants who left the study, 13 did so because of adverse events.
  • Phase 2 is published in the Lancet in 2025: a 48-week double-blind, randomised, placebo-controlled trial in 263 adults with obesity, or overweight with a related condition, and without type 2 diabetes, at 46 centres in the United States (PMID 41207310). The primary endpoint was percent change in body weight at 48 weeks. On the efficacy estimand the mean change ranged from 9% to 20% across six eloralintide arms, against 0.4% on placebo. Nausea was reported by 11% to 64% of participants across eloralintide arms and 14% on placebo, and fatigue by 0% to 46% against 12%; the spread followed how each arm was started as well as where it ended, rather than rising steadily.
  • Phase 2b in type 2 diabetes (NCT06603571) has a company topline only, presented at the EASD meeting and released on 30 September 2026: in 367 adults with type 2 diabetes over 48 weeks, the highest combination arm of eloralintide with GLP-2 TZ recorded a 23.3% mean reduction in body weight, against 14.8% for GLP-2 TZ alone at its top level and 3.0% for placebo, on the efficacy estimand. Discontinuation for adverse events ranged from 10.8% to 27.0% in the combination arms and was 16.7% on placebo. It has not been peer reviewed, and a press release reports no confidence intervals.
  • Context and comparison appear in several 2026 reviews, including a review of amylin analogues and early-phase clinical trials in Diabetes, Obesity and Metabolism (PMID 42452898), a network meta-analysis of amylin-based therapies (PMID 42175595), a review in Pharmacological Research on amylin-based pharmacotherapy and tolerability (PMID 42586227), and a review in Cardiology in Review on cardiometabolic implications (PMID 42745233).

Two things to carry away from that trial rather than the headline figure. Which estimand is quoted changes the number: a trial of this design reports both an efficacy estimand, which asks what happened in participants who stayed on treatment, and a treatment-policy estimand, which counts everyone regardless. Summaries that quote the larger figure without naming the estimand are not wrong so much as incomplete, and reading peptide trial results is about exactly this. And 48 weeks is long enough to speak to durability, which is unusual in a phase 2 trial in this field.

How it sits among the amylin compounds

Eloralintide is not alone in its class, and the comparison is the one most readers are actually making.

CompoundOriginatorClassStatus, 14 Nov 2026
Eloralintide (LY3841136)Eli LillySelective amylin receptor agonist (AMY1-preferring)Eight phase 3 trials, six recruiting
CagrilintideNovo NordiskAmylin and calcitonin receptor agonistPhase 3 alone (RENEW programme, from November 2025) and in combination (REDEFINE programme, several trials completed)
PetrelintideZealand Pharma, with Roche as phase 3 sponsorAmylin receptor agonistThree phase 3 trials (ZUPREME-3, -4 and -5) recruiting since September and October 2026
PramlintideAmylin PharmaceuticalsAmylin analogueFDA-approved March 2005; Drugs@FDA now lists every strength as discontinued; no entry in Canada's Drug Product Database

Pramlintide is the one that matters for calibration: an amylin analogue was approved in the United States in 2005, and its application, now held by AstraZeneca, is listed on Drugs@FDA with every strength discontinued, with a marketing end date of January 2027 in FDA's product directory. It has no entry in Canada's Drug Product Database. What is new in this generation is the receptor selectivity and the longer duration of action, not the idea of addressing the amylin system. The reviews appearing alongside the phase 2 publication consistently frame the class in terms of tolerability relative to existing options, which is the clinical question it is being developed to answer.

Important note: the compound holds no marketing authorization in any jurisdiction, its phase 3 programme is incomplete, and nothing in the published record is a statement about research-grade material.

Why This Is the Hardest Compound Here to Verify

Every other compound in this series can be checked against something external. Oxytocin has seventy years of settled chemistry and an authorized pharmaceutical product. BPC-157, ipamorelin and the GHRH analogues have registry entries, published formulas and decades of analytical literature. Even Cerebrolysin, which has no formula at all, has a characterization method published for it.

A compound in active phase 3 development has a different problem. The structure is known from the discovery publication and the registry record, so an expected mass exists. What does not exist is the surrounding infrastructure: no pharmacopoeial monograph specifies what a compliant lot looks like, no compendial method is prescribed, and no independent reference standard is in general circulation outside the originator's own supply chain. The originator has all of that; nobody else does.

So the verification questions are sharper than usual:

Ask what reference standard the identity was established against. The monoisotopic mass is 4523.2604 Da and the formula is C201H319N49O65S2, so a mass spectrometric result can be compared against a computed expectation. That is a weaker check than comparison against a characterized standard, and the certificate should be explicit about which was done. The methods are set out in what actually proves a peptide sequence. Laboratories that can be commissioned independently are listed under independent testing laboratories.

At 4526 daltons, purity is genuinely informative. This is the opposite of the situation for a tripeptide. A long peptide has many positions at which synthesis can fail, and deletion and truncation impurities will appear on a chromatogram. A purity figure here carries real information, unlike for KPV or ipamorelin.

Confirm the bridge and the lipid, because each has a near-miss with a different mass. Eloralintide's ring is a methylene thioacetal, so a lot synthesised with an ordinary disulfide instead would be about 14 daltons lighter, and a lot missing the fatty-acid side chain would be lighter by far more. Both are easy mistakes for a manufacturer working without the originator's process, and only an intact-mass measurement distinguishes them; a chromatographic purity figure does not. The lipid also changes how the molecule behaves on a reversed-phase column, so a method developed for an unmodified peptide may not be the right one. Ask what the measured mass was and what expected value it was compared against.

Net peptide content matters at this size. A 4526-dalton peptide supplied as a salt carries proportionally more counterion and water than the numbers suggest, as chain length and counterion explains, and the figure determines the mass actually weighed out.

Check the three things that make a certificate checkable:

  1. The laboratory is named, with its report number.
  2. The lot number on the document matches the vial in your hand.
  3. The laboratory publishes a verification page where the report number can be looked up independently.

A certificate that names no laboratory, or whose lot number matches nothing on the container, is a document about some other material. Volta publishes its certificates as page images in its published certificate archive with the issuing laboratory's own verification link, and a certificate for the batch you receive is available on request. Those reports carry both HPLC and mass spectrometry results.

Eloralintide on the Shelf

Eloralintide is listed as a single 10 mg vial and appears in no multi-component product.

That is the right arrangement for a compound whose own clinical programme is still establishing what it does on its own. Combination work is part of that programme, with phase 1 and phase 3 studies examining it alongside an incretin receptor agonist, but those are protocol-controlled investigations of a specific pairing at specific exposures, which is a different thing from a vial containing two compounds in a fixed ratio.

Compared against the rest of the shelf, eloralintide inverts the usual trade-off. The compounds with the longest analytical history mostly have the weakest clinical evidence: BPC-157 has hundreds of papers and no human efficacy trial; ipamorelin has a 1998 characterization and nothing since. Eloralintide has a randomised 48-week trial in a major journal and a recruiting phase 3 programme, and almost no independent analytical infrastructure. Neither position is better than the other. They are different kinds of uncertainty, and a buyer should know which one they are taking on.

Frequently Asked Questions

What is eloralintide?

Eloralintide, development code LY3841136, is a selective amylin receptor agonist developed by Eli Lilly and Company. Its CAS number is 2883634-40-8, its formula is C201H319N49O65S2 and its average mass is 4526 g/mol.

Is eloralintide the same class as the incretin compounds?

No, and it is not a GLP-1 receptor agonist. Amylin is co-secreted with insulin from pancreatic beta cells and acts at receptor complexes built on the calcitonin receptor with receptor activity-modifying proteins. The incretins are gut-derived hormones acting at their own receptors. They are distinct hormones with distinct targets, which is why the clinical programme includes combination studies.

What were the eloralintide phase 2 results?

The 48-week phase 2 trial in 263 adults without type 2 diabetes, published in the Lancet in 2025, reported mean changes in body weight of 9% to 20% across eloralintide arms against 0.4% on placebo, on the efficacy estimand, with nausea reported by 11% to 64% of participants across arms against 14% on placebo. Any single percentage quoted from it should be read with the estimand attached.

Is eloralintide in phase 3?

Yes. Eight phase 3 trials carry its name, six under ENLIGHTEN for the single agent and two under AMPLIFY for a combination with GLP-2 TZ. Six were recruiting and two not yet recruiting as of 14 November 2026. Primary completion dates run from January 2028 to November 2029.

How does eloralintide compare with GLP-3 RT?

They are different classes. Eloralintide is a selective amylin receptor agonist; GLP-3 RT acts at incretin and glucagon receptors. Their trials were run separately with different designs and populations, so cross-trial comparisons of headline percentages compare studies rather than compounds.

What is the difference between eloralintide and cagrilintide?

Both are long-acting, fatty-acid-acylated amylin analogues, but they are built to different receptor profiles and different chemistry. Eloralintide is AMY1-preferring, 12-fold over the calcitonin receptor in human cell assays, and closes its ring with a thioacetal; cagrilintide is a non-selective agonist active at amylin and calcitonin receptors and keeps a disulfide. In lean rats, eloralintide produced less conditioned taste avoidance than cagrilintide. Both are in phase 3, and neither has an entry in Health Canada's Drug Product Database.

Is eloralintide a peptide?

Yes. It is a lipidated peptide of about 4,526 daltons, with a ring closed by a methylene thioacetal between two cysteines and a twenty-carbon fatty diacid attached through a linker.

Does eloralintide have Canadian clinical trial sites?

Yes. On ClinicalTrials.gov, four of its eight phase 3 trials list Canadian sites: ENLIGHTEN-1, ENLIGHTEN-3, ENLIGHTEN-4 and ENLIGHTEN-10. Health Canada has not authorized any eloralintide product.

When could eloralintide be approved?

No approval date can be stated. The single-agent phase 3 trials list primary completion dates in 2028 and the combination and cardiovascular trials in late 2029, and a regulatory submission follows completion rather than accompanying it.

Is eloralintide FDA-approved?

No. It holds no marketing authorization in any jurisdiction. As of 14 November 2026 it is in an active phase 3 programme with six trials recruiting, which means the evidence package a regulator reviews is not complete.

Why is a compound in development harder to verify?

Because the external infrastructure does not exist yet. No pharmacopoeial monograph specifies what a compliant lot looks like, no compendial method is prescribed, and no independent reference standard circulates outside the originator's supply chain. An expected mass can be computed from the published formula, but comparison against a computed value is a weaker check than comparison against a characterized standard.

Is a purity figure useful for eloralintide?

Yes, more so than for most compounds on a research shelf. At 4526 daltons the molecule has many positions at which synthesis can fail, so deletion and truncation impurities appear on a chromatogram and a purity figure carries real information. What purity cannot show is whether the thioacetal bridge and the fatty-acid side chain are the right ones; that needs an intact mass compared against the expected 4523.26 Da monoisotopic value.

Sources

  • PubChem Compound Summary, CID 175663130 (Eloralintide). National Library of Medicine. CAS number, formula, average mass, monoisotopic mass, and the structure (methylene thioacetal ring, C20 diacid acylation) as cited above. Retrieved 14 November 2026.
  • PubChem Compound Summaries, CID 171397054 (cagrilintide) and CID 16132430 (amylin, human). Formula, average mass and ring chemistry as cited above. Retrieved 14 November 2026.
  • ClinicalTrials.gov v2 API, searches for "eloralintide" and "LY3841136", checked 14 November 2026: 26 studies. Phase 3: NCT07321886 (ENLIGHTEN-1), NCT07282600 (ENLIGHTEN-2), NCT07369011 (ENLIGHTEN-3), NCT07353931 (ENLIGHTEN-4), NCT07392190 (ENLIGHTEN-6), NCT07900633 (ENLIGHTEN-10), NCT07881432 (AMPLIFY-1), NCT07881458 (AMPLIFY-2). Phase 2: NCT06230523 (completed), NCT06603571 (completed), NCT07215559, NCT07589608, NCT06143956. Phase 1: NCT05295940, NCT06916065, NCT07738614, NCT07701083, NCT07935304. Sponsor Eli Lilly and Company.
  • Eli Lilly and Company. Press release, 30 September 2026, phase 2b results of eloralintide with [GLP-2 TZ] in adults with obesity or overweight and type 2 diabetes (NCT06603571), presented at the 62nd EASD Annual Meeting. PR Newswire release no. 302894480, retrieved 14 November 2026.
  • ClinicalTrials.gov, cagrilintide RENEW 1 (NCT07220642), RENEW 2 (NCT07220759), RENEW 4 (NCT07745504) and REDEFINE 2 (NCT05394519); petrelintide ZUPREME-3 (NCT07843498), ZUPREME-4 (NCT07843485) and ZUPREME-5 (NCT07843472). Checked 14 November 2026.
  • US Food and Drug Administration, Drugs@FDA, NDA 021332 (pramlintide), approved 16 March 2005, all strengths listed as discontinued; openFDA NDC Directory, marketing end date 31 January 2027. Retrieved 14 November 2026.
  • Health Canada Drug Product Database, active ingredient searches for eloralintide, cagrilintide, petrelintide and pramlintide, 14 November 2026: no entries.
  • Molecular Metabolism. 2025. "Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept." PMID 41109426.
  • The Lancet. 2025. "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial." PMID 41207310.
  • Diabetes, Obesity and Metabolism. 2026. "Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept." PMID 41559929.
  • Diabetes, Obesity and Metabolism. 2026. "Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials." PMID 42452898.
  • Endocrinology, Diabetes and Metabolism. 2026. "Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis." PMID 42175595.
  • Pharmacological Research. 2026. "Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs." PMID 42586227.
  • Cardiology in Review. 2026. "Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide." PMID 42745233.

Note on the titles above: two of the cited papers carry consumer phrasing in their own titles, which this post does not use in its own prose. The titles are quoted as published.

Research Use Only. This article is provided for informational and educational purposes only. The compounds and topics discussed are intended solely for laboratory and scientific research. This content does not constitute medical advice, and Volta Peptides does not endorse or promote human consumption of any research compound.

About the author

Marcus Hopkin, PhD, Director of Research and Development at Volta Peptides.

Marcus Hopkin, PhD

Director of Research and Development, Volta Peptides

Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.

Marcus wrote this article, last reviewed November 10, 2026. It is in-house scientific writing by a named member of staff and is not peer review, independent third-party review or medical advice.

Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.